Edesa Biotech is a biotechnology business based in the US. Edesa Biotech shares (EDSA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.21 – an increase of 0.45% over the previous week. Edesa Biotech employs 16 staff and has a trailing 12-month revenue of around $500.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.21 |
|---|---|
| 52-week range | $2.05 - $6.46 |
| 50-day moving average | $3.54 |
| 200-day moving average | $4.30 |
| Wall St. target price | $20.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-19.78 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.15 from 2024-11-25
| 1 week (2024-11-18) | -2.23% |
|---|---|
| 1 month (2024-10-25) | -36.76% |
| 3 months (2024-08-23) | -51.69% |
| 6 months (2024-05-24) | -50.91% |
| 1 year (2023-11-24) | -33.85% |
|---|---|
| 2 years (2022-11-25) | -65.87% |
| 3 years (2021-11-26) | 45.78 |
| 5 years (2019-11-26) | 34.3 |
| Revenue TTM | $500 |
|---|---|
| Gross profit TTM | $311,200 |
| Return on assets TTM | -71.52% |
| Return on equity TTM | -129.29% |
| Profit margin | 0% |
| Book value | $0.88 |
| Market Capitalization | $7 million |
TTM: trailing 12 months
We're not expecting Edesa Biotech to pay a dividend over the next 12 months.
Edesa Biotech's shares were split on a 1:7 basis on 10 October 2023 . So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Edesa Biotech shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Edesa Biotech shares which in turn could have impacted Edesa Biotech's share price.
Over the last 12 months, Edesa Biotech's shares have ranged in value from as little as $2.05 up to $6.46. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Edesa Biotech's is 0.838. This would suggest that Edesa Biotech's shares are less volatile than average (for this exchange).
Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.